Search
Close this search box.

Venture report: Big rounds for Bluejay, Attovia and Zenas

ARTICLE | Finance

Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT

By Paul Bonanos, Director of Biopharma Intelligence

May 9, 2024 10:24 PM UTC

In a busy week for venture fundings, Bluejay, Attovia and Zenas all drew nine-figure rounds to advance programs in the clinic, while Flagship introduced a new start-up to explore the viral proteome.

Frazier Life Sciences and an undisclosed firm co-led the $182 million series C announced Thursday by Bluejay Therapeutics Inc., with crossover investors joining the round. Bluejay is conducting a Phase I/II trial of HBsAg-targeting antibody BJT-778 to treat chronic hepatitis D viral infection…